Evidence map›Paper›PMID 40830921›Full record

ArticleChinese medical journal2026

Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

Hanwei Mei, Minghan Qiu, Ruxue Liu, Teng Song, Zhanhua Gao, Qiaonan Zhang, Yayun Wang, Jie Hao, Ming Gao, Zhen Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanwei MeiDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Minghan QiuDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Ruxue LiuDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Teng SongDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Zhanhua GaoSchool of Medicine, Nankai University, Tianjin 300071, China.
Qiaonan ZhangSchool of Medicine, Nankai University, Tianjin 300071, China.
Yayun WangCollege of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300121, China.
Jie HaoTianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Ming GaoTianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Zhen YangTianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Huaqing WangDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is characterized by high aggressiveness and rapid growth. Erianin, a natural compound derived from the Chinese herb Dendrobium , has been shown to exhibit anticancer effects in certain types of cancer; however, its role and mechanism of action in DLBCL have not yet been reported. Therefore, this study aimed to investigate the potential of erianin as a therapeutic drug for DLBCL.

methodsThe cell counting kit-8 assay, lactate dehydrogenase release assay, flow cytometry, and 5-ethynyl-2'-deoxyuridine (EdU) assay were used to assess the inhibitory effect of erianin on DLBCL cells. RNA sequencing, western blotting, immunofluorescence, and flow cytometry were used to investigate the molecular mechanisms of the effect of erianin on DLBCL cells. Erianin was labeled with biotin or rhodamine, and its target proteins were identified using pull-down assays combined with proteomics, cellular thermal shift assays, and molecular docking. CompuSyn software was used to analyze the combination index of erianin and doxorubicin (DOX) for evaluating their synergistic anti-DLBCL effects. Results from the in vitro experiments were subsequently validated using in vivo experiments.

resultsErianin inhibited the proliferation of DLBCL cells, promoted G2/M phase arrest, and induced cell death. Mechanistically, erianin induced inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in DLBCL cells, which led to increased reactive oxygen species (ROS) formation, inflammasome activation, and caspase-1/Gasdermin D (GSDMD)-dependent pyroptosis. Erianin was found to bind to the S100A9 protein, suggesting a potential mechanism through which erianin activates downstream signaling pathways. Moreover, erianin synergistically enhanced the effects of DOX on DLBCL.

conclusionsOur study demonstrates that erianin binds to S100A9 and suppresses the PI3K/AKT signaling pathway in DLBCL cells, thereby elevating ROS levels, activating the inflammasome, and triggering caspase-1/GSDMD-dependent pyroptosis. Moreover, erianin increased the sensitivity of DLBCL cells to DOX both in vitro and in vivo . The effects of erianin on DLBCL imply its potential in the development of promising new drugs against this disease.

Indexed as

BibenzylsDoxorubicinLymphoma, Large B-Cell, DiffusePhenolPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPyroptosisAnimalsCell Line, TumorCell ProliferationDrug SynergismGasderminsHumansSignal TransductionBibenzylsDoxorubicinErianinGasderminsPhenolPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDiffuse large B-cell lymphomaDoxorubicinErianinPI3K/AKTTraditional Chinese herbs

Identifiers

PMID40830921
PMCPMC13593181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.